AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Neuronetics Q2 2025: Navigating Contradictions in Marketing Strategies and Revenue Expectations
Generated by AI AgentEarnings Decrypt
Tuesday, Aug 5, 2025 1:05 pm ET1min read
Aime SummaryMarketing strategy and SPRAVATO buy and bill, TMS and SPRAVATO revenue mix at Greenbrook, marketing strategy for traditional STIM business, Greenbrook's contribution to revenue, and revenue growth and seasonality are the key contradictions discussed in Neuronetics' latest 2025Q2 earnings call.
Revenue Growth and Greenbrook Integration:
- reported total revenue of $38.1 million in Q2 2025, an 18% year-over-year increase on an adjusted pro forma basis.
- Growth was driven by the strength of the Greenbrook clinic business, generating $23 million in revenue, and the integration of Greenbrook operations following the acquisition.
Operational Efficiency and Cash Collections:
- Neuronetics improved cash collections, reducing cash used in operations to $3.5 million, better than the previous target of under $5 million.
- This was achieved through initiatives to address legacy issues with payers, improve claim submission accuracy, and optimize patient flow with self-check-in programs.
SPRAVATO Rollout and Billing Strategy:
- The rollout of SPRAVATO continues with 77 of 83 eligible clinics now offering the therapy.
- The company is taking a more analytical approach to its buy and bill model expansion, focusing on opportunities that deliver good margins based on varying payer reimbursement rates.
Adolescent Growth and Marketing Strategy:
- Neuronetics saw 25% growth in adolescent new patient starts in the first half of 2025 compared to 2024, driven by expanded insurance coverage.
- The company is focusing on educating primary care physicians about the benefits of referring patients for NeuroStar treatment, driven by the Provider Connection Program.
Financial Guidance and Cash Flow Management:
- Neuronetics expects net revenue of $37 million to $39 million for Q3 and targets cash flow from operations to be in the range of negative $3 million to breakeven in Q3, turning positive in Q4.
- This is based on the successful optimization of SPRAVATO buy and bill reimbursements and ongoing operational efficiency improvements.
Revenue Growth and Greenbrook Integration:
- reported total revenue of $38.1 million in Q2 2025, an 18% year-over-year increase on an adjusted pro forma basis.
- Growth was driven by the strength of the Greenbrook clinic business, generating $23 million in revenue, and the integration of Greenbrook operations following the acquisition.
Operational Efficiency and Cash Collections:
- Neuronetics improved cash collections, reducing cash used in operations to $3.5 million, better than the previous target of under $5 million.
- This was achieved through initiatives to address legacy issues with payers, improve claim submission accuracy, and optimize patient flow with self-check-in programs.
SPRAVATO Rollout and Billing Strategy:
- The rollout of SPRAVATO continues with 77 of 83 eligible clinics now offering the therapy.
- The company is taking a more analytical approach to its buy and bill model expansion, focusing on opportunities that deliver good margins based on varying payer reimbursement rates.
Adolescent Growth and Marketing Strategy:
- Neuronetics saw 25% growth in adolescent new patient starts in the first half of 2025 compared to 2024, driven by expanded insurance coverage.
- The company is focusing on educating primary care physicians about the benefits of referring patients for NeuroStar treatment, driven by the Provider Connection Program.
Financial Guidance and Cash Flow Management:
- Neuronetics expects net revenue of $37 million to $39 million for Q3 and targets cash flow from operations to be in the range of negative $3 million to breakeven in Q3, turning positive in Q4.
- This is based on the successful optimization of SPRAVATO buy and bill reimbursements and ongoing operational efficiency improvements.
Earnings Decrypt
Discover what executives don't want to reveal in conference calls
Latest Articles
ServiceTitan's Q3 2026: Contradictions Emerge on MAX Program, Residential HVAC GTV, AI Strategy, Tariff Impact, and Growth Strategy
Dec.05 2025
Rubrik's Q3 2026: Contradictions Emerge on Growth Strategy, Non-Cloud ARR, Market Position, and Identity Security
Dec.05 2025
Stitch Fix's 2026 Q1 Earnings Call: Contradictions Emerge on Gross Margins, Advertising Strategies, and Client Acquisition
Dec.05 2025
CooperVision's Q4 2025: Contradictions Emerge on Growth Expectations, Contact Lens Market Projections, MyDay Margins, Fertility Sales, and Inventory Dynamics
Dec.05 2025
Zumiez's Q3 2026: Contradictions in Skate Hardgoods, Private Label, Footwear, and Growth Outlook
Dec.05 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments

No comments yet